Atrial Fibrillation - Limited efficacy and poor safety lead to bleak outlook

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-10-09

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Datamonitor estimates that there are over 11 million atrial fibrillation patients in the seven major markets. Despite high unmet needs and limitations of all the current treatment options, achievement of regulatory approval is becoming increasingly difficult. This means that a very limited number of novel treatments are expected to be introduced in the near future.


Scope

  • Review of the available epidemiology data to assess the patient population of atrial fibrillation and to segment the patient population by type
  • Outline of the existing therapy options and current prescribing trends
  • Assessment of the current status of the rhythm versus rate control debate and the determining factors for each type of treatment strategy
  • Evaluation of the current usage of cardiac rhythm devices and ablation techniques to determine their future role in atrial fibrillation management


    • Report Highlights
    The rapid increase in atrial fibrillation prevalence is driven by a number of factors, namely ageing population, the obesity epidemic, better prevention of strokes, and better survival of patients with cardiac disease.

    There are numerous unmet needs associated with every treatment option available. The main unmet needs of pharmacological therapy are insufficient efficacy and poor safety. Non-pharmacological therapy has severe limitations, among them the cost of the procedures and the fact that a limited number of patients are eligible for it.

    Despite the desperate need for a new efficacious and safe antiarrhythmic, no new drug that would significantly impact atrial fibrillation management is going to appear in the nearest future.


    Reasons to Purchase

  • Target physicians more effectively, through an understanding of treatment options and their prescription choices
  • Assess the potential of each treatment option in the management of atrial fibrillation and understand the dynamics of the market
  • Recognize lucrative target populations, in terms of unmet need and patient potential, in order to successfully position developmental products

    • Table of Contents

    Other users found this report page using the following search terms: arrhythmia atrial fibrillation ventricular fibrillation pacemaker atrial fibrillation outlook af vein isolation cardioversion driving pulmonary catheter

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.